TBPH — Theravance Biopharma Share News
0.000.00%
Last trade - 00:00- $883.66m
- $528.80m
- $107.46m
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:26 AM
Theravance Biopharma marginally beats Q3 revenue estimates, YUPELRI sales up 15%
Brief: Theravance Biopharma Q3 Operating Income USD -6.455 Million
Brief: Theravance Biopharma Inc - Co And Mylan Settle With Cipla Over Yupelri Inhalation Solution - SEC Filing
Theravance Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Theravance Biopharma Q2 Operating Income USD -2.725 Million
Theravance Biopharma Inc expected to post earnings of 67 cents a share - Earnings Preview
Brief: Theravance Biopharma Announces Approval Of Yupelri By China's NMPA
Brief: Theravance Biopharma - Theravance And Mylan Enter Settlement Agreement With Eugia - SEC Filing
Brief: Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Theravance Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Theravance Biopharma Q1 Operating Income USD -14.434 Million
Theravance Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview
Theravance Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Theravance Biopharma Q4 Operating Income USD -9.2 Million
Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview
Theravance Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Theravance Biopharma Q3 Operating Income USD -10.837 Million
Theravance Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview